65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014 Reported by Jules Levin AASLD 2014 Nov 7-11 Boston Fred Lahser1, Karin Bystol1, Stephanie Curry1, Patricia McMonagle1, Rong Liu1, Ellen ... National AIDS Treatment Advocacy Project, 1 month ago
C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8472) + Sofosbuvir in Treatment-Nave Patients with Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6 or 8 Weeks (Interim Results) - National AIDS Treatment Advocacy Project, 1 month ago
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
The Lancet, Early Online Publication, 11 November 2014 Eric Lawitz, Edward Gane, Brian Pearlman, Edward Tam, Wayne Ghesquiere, Dominique Guyader, Laurent Alric, Jean-Pierre Bronowicki, Laura Lester, William Sievert, Reem Ghalib, Luis Balart, ...National AIDS Treatment Advocacy Project, 1 month ago Excellent Results for 12 and 18 Weeks of Merck's Dual Hep C Regimen AIDSmeds, 1 month ago Merck (MRK) Updates on MK-5172/MK-8742 Phase 2 Wall Street Business Network, 1 month ago Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B) National AIDS Treatment Advocacy Project, 1 month ago
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th...
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th American Association for the Study of Liver Diseases Annual Meeting By a News Reporter-Staff News ...4 Traders, 2 months ago Merck Posts Data For Triple-Drug HCV Regimen Bioresearch Online, 1 month ago MERCK : Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients 4 Traders, 1 month ago Merck & Co.???s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir In Combination With A Nucleotide Inhibitor (C-SWIFT Study) Presented At The Liver Meeting?? BioSpace, 1 month ago
For shareholders of Gilead Sciences (NASDAQ: GILD Gilead's giant leap forward Sovaldi and Harvoni both represent major breakthroughs in HCV patient quality of care in that neither Sovaldi (geared toward genotype 2 and 3 HCV) nor Harvoni (targeted ...Motley Fool, 1 day ago Sovaldi Can't Sustain The Current Prices Of Gilead Sciences' Stock: Algorithmic And Fundamental Analysis Seeking Alpha, 1 week ago Is AbbVie's Bullishness On Its Hepatitis C Drugs Valid? Seeking Alpha, 1 month ago
GILD data by YCharts Despite last weeks' oil-induced swoon, the S&P 500 is still up by 8% for the year. But don't bother bragging about this to Gilead Sciences shareholders -- through the weekend, Gilead shares had nearly quintupled the broader ...Nasdaq, 3 days ago
Bourlière M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without RBV. Program and abstracts of the 65th annual meeting of the ...General Medicine eJournal, 1 week ago
65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014 Feedback from the real-world: do HCV cure rates in real-life patient cohorts hold what clinical trials promised? Summary from AASLD 2014 ...National AIDS Treatment Advocacy Project, 2 weeks ago
Source: Merck & Co. It's been about a month since pharmaceutical giant Merck (NYSE: MRK ) reported its third-quarter results, but time hasn't changed the fact that Merck's been struggling mightily with patent expirations and increased competition ...Citybizlist, 3 weeks ago Do Merck's Recent Hepatits C Trial Results Weaken Its Position? Trefis, 1 month ago Merck's triple-therapy hepatitis C regimen shows sub-optimal efficacy Pharma Letter, 1 month ago Merck Reports Interim Data on Hepatitis C Virus Drug Yahoo! Finance, 1 month ago
More from: , BioSpace...and 1 other sources
Heyneman D. Immunology of leishmaniasis. Bull. World Health Organ. 44(4), 499514 (1971). Antoine JC, Prina E, Lang T et al. The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Trends ...Medscape, 1 month ago
Gastroenterology Published: Nov 16, 2014 BOSTON -- A new study suggests that some subgroups of patients with hepatitis C (HCV) infection can achieve sustained virologic responses (SVR) in as short as 4 weeks using an aggressive, investigational ...MedPage Today, 1 month ago Shorter Treatment Shows Promise With Investigative HCV Agents MedPage Today, 1 month ago
on your WebpageAdd Widget >Get your members hooked!